Perflutren - Lantheus Medical Imaging

Drug Profile

Perflutren - Lantheus Medical Imaging

Alternative Names: Definity; Definity Vial; DMP 115; Luminity; MRX-115; Perflutren (PEG); Perflutren Lipid Microsphere; YM 454

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaRx Therapeutics
  • Developer Astellas Pharma; Lantheus Medical Imaging
  • Class Contrast media; Fluorocarbons
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders

Most Recent Events

  • 02 Feb 2017 US FDA approves label update for perflutren
  • 15 Dec 2016 Biomarkers information updated
  • 12 Aug 2016 Launched for Cardiovascular disorders (Diagnosis) in New Zealand, Australia (IV) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top